Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H6NO2.Na |
| Molecular Weight | 111.075 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CNCC([O-])=O
InChI
InChIKey=ZUFONQSOSYEWCN-UHFFFAOYSA-M
InChI=1S/C3H7NO2.Na/c1-4-2-3(5)6;/h4H,2H2,1H3,(H,5,6);/q;+1/p-1
| Molecular Formula | C3H6NO2 |
| Molecular Weight | 88.0852 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sarcosine, also known as N-methylglycine, is a metabolite of glycine. It shares properties with both glycine and D-serine, though its effects are weaker.
Sarcosine supplementation can be used to alleviate symptoms of depression and schizophrenia, or improve cognition. It is absorbed more reliably by the body than D-serine, which can also treat similar conditions. Sarcosine is being investigated for its connection to prostate cancer. It may be a biomarker for prostate cancer, which means that if sarcosine levels in the blood are higher than normal, it could be an indicator of prostate cancer. This doesn’t mean that sarcosine itself causes cancer. More research is needed to confirm this relationship. Sarcosine’s main mechanism involves inhibiting a transporter, called GlyT1, which takes up glycine and D-serine into cells. This increases the levels of glycine and D-serine in the body and increases their effects. Sarcosine, a glycine transporter type 1 inhibitor and an N-methyl-D-aspartate (NMDA) receptor co-agonist at the glycine binding site, potentiates NMDA receptor function. Sarcosine is an inhibitory glycine receptor agonist.
Approval Year
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25841105/ |
4 g 1 times / day multiple, oral dose: 4 g route of administration: Oral experiment type: MULTIPLE co-administered: |
SARCOSINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Okadaic acid-induced, naringin-sensitive phosphorylation of glycine N-methyltransferase in isolated rat hepatocytes. | 2003-07-15 |
|
| New N-RAP-binding partners alpha-actinin, filamin and Krp1 detected by yeast two-hybrid screening: implications for myofibril assembly. | 2003-06-01 |
|
| Optimized conventional synthesis of "RGD" and "RGDS" peptides and their sarcosine mimics as integrin GP IIb/IIIa antagonists. | 2003-06 |
|
| Sarcosine-maleic acid (1:1) crystal: structure, 13C NMR and vibrational properties, protonation character. | 2003-06 |
|
| Modeling anhydrous and aqua copper(II) amino acid complexes: a new molecular mechanics force field parametrization based on quantum chemical studies and experimental crystal data. | 2003-04-07 |
|
| [3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. | 2003-04-07 |
|
| Kinetic mechanisms of glycine oxidase from Bacillus subtilis. | 2003-04 |
|
| Role of EphA4 and EphrinB3 in local neuronal circuits that control walking. | 2003-03-21 |
|
| Structural and mechanistic studies on ThiO, a glycine oxidase essential for thiamin biosynthesis in Bacillus subtilis. | 2003-03-18 |
|
| The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. | 2003-03 |
|
| Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. | 2003-03 |
|
| A hydrophobicity scale for the lipid bilayer barrier domain from peptide permeabilities: nonadditivities in residue contributions. | 2003-02-18 |
|
| Isolation and functional characterization of N-methyltransferases that catalyze betaine synthesis from glycine in a halotolerant photosynthetic organism Aphanothece halophytica. | 2003-02-14 |
|
| Synthesis, antimicrobial and antifungal activity of a new class of spiro pyrrolidines. | 2003-02-06 |
|
| Tautomeric rearrangement of a dihydroflavin bound to monomeric sarcosine oxidase or N-methyltryptophan oxidase. | 2003-02-04 |
|
| Microfabricated electrophoresis chip for bioassay of renal markers. | 2003-02-01 |
|
| Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. | 2003-02 |
|
| Determination of choline, betaine, and dimethylglycine in plasma by a high-throughput method based on normal-phase chromatography-tandem mass spectrometry. | 2003-02 |
|
| Pt(II) and Pd(II) derivatives of ter-butylsarcosinedithiocarbamate. Synthesis, chemical and biological characterization and in vitro nephrotoxicity. | 2003-01-15 |
|
| Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. | 2003-01 |
|
| The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. | 2003-01 |
|
| Conjugated bile acid replacement therapy reduces urinary oxalate excretion in short bowel syndrome. | 2003-01 |
|
| Molecular characterization of NikD, a new flavoenzyme important in the biosynthesis of nikkomycin antibiotics. | 2002-12-31 |
|
| Efficacy of macromolecular crowding in forcing proteins to fold. | 2002-12-10 |
|
| Simultaneous horizontal gene transfer of a gene coding for ribosomal protein l27 and operational genes in Arthrobacter sp. | 2002-12 |
|
| Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. | 2002-12 |
|
| Ion conductors derived from biogenic amines, bile acids, and amino acids. | 2002-11-21 |
|
| Hydrophobicity and helicity of membrane-interactive peptides containing peptoid residues. | 2002-11-15 |
|
| Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. | 2002-11-01 |
|
| Glycine receptors and transporters on bullfrog retinal Müller cells. | 2002-09-16 |
|
| Promoter escape by RNA polymerase II. | 2002-09-13 |
|
| Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. | 2002-09 |
|
| Synthesis, characterization and in vitro cytotoxicity of new organotin(IV) derivatives of N-methylglycine. | 2002-08-15 |
|
| Monomeric sarcosine oxidase: role of histidine 269 in catalysis. | 2002-08-06 |
|
| Monomeric sarcosine oxidase: evidence for an ionizable group in the E.S complex. | 2002-08-06 |
|
| Argyrins, immunosuppressive cyclic peptides from myxobacteria. II. Structure elucidation and stereochemistry. | 2002-08 |
|
| Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. | 2002-08 |
|
| A new conceptual framework for enzyme catalysis. Hydrogen tunnelling coupled to enzyme dynamics in flavoprotein and quinoprotein enzymes. | 2002-07 |
|
| Assay of the concentration and (13)C isotopic enrichment of propionyl-CoA, methylmalonyl-CoA, and succinyl-CoA by gas chromatography-mass spectrometry. | 2002-06-01 |
|
| 1H and (13)C NMR spectroscopic analysis of human saliva. | 2002-06 |
|
| Peptoid residues and beta-turn formation. | 2002-06 |
|
| Mechanistic aspects of the covalent flavoprotein dimethylglycine oxidase of Arthrobacter globiformis studied by stopped-flow spectrophotometry. | 2002-04-09 |
|
| An unexpected Diels-Alder reaction on the fullerene core rather than an expected 1,3-dipolar cycloaddition. | 2002-04-07 |
|
| Detergent extract from chlamydial elementary bodies used as antigen for enzyme-linked immunosorbent assay. | 2002-04 |
|
| Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. | 2002-04 |
|
| Single crystal EPR studies on Mn(II)-doped sarcosine cadmium chloride and sarcosine cadmium bromide: study of zero-field splitting tensor in iso-structural complexes. | 2002-02 |
|
| Biosensors and flow-through system for the determination of creatinine in hemodialysate. | 2002-01 |
|
| Cofactors in sarcosine oxidase from Corynebacterium sp. U-96. | 2002-01 |
|
| Lysosomotropic N,N- dimethyl alpha-aminoacid N-alkyl esters and their quaternary ammonium salts as plasma membrane and mitochondrial ATPases inhibitors. | 2002 |
|
| Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031). | 2001-06 |
Patents
Sample Use Guides
The standard sarcosine dose is 30mg/kg of bodyweight, which correlates to an approximate dosage range of 2,045 – 2,727 mg for people between 150 – 200 lbs.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:56:29 GMT 2025
by
admin
on
Mon Mar 31 19:56:29 GMT 2025
|
| Record UNII |
6EHN3PQL8Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10480
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | |||
|
m9780
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID5027568
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | |||
|
23667259
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | |||
|
224-338-5
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | |||
|
6EHN3PQL8Z
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | |||
|
4316-73-8
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | |||
|
6EHN3PQL8Z
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | |||
|
1364526
Created by
admin on Mon Mar 31 19:56:29 GMT 2025 , Edited by admin on Mon Mar 31 19:56:29 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
